Dapagliflozin (CAS 461432-26-8) is a high-purity, pharmaceutical-grade SGLT2 inhibitor synthesized via advanced green chemistry processes, complying with strict USP and EP quality standards. Its molecular structure is optimized to selectively block sodium-glucose transporters in the kidneys, promoting urinary glucose excretion to lower blood sugar levels without stimulating insulin secretion. Produced with zero heavy metal residues and minimal organic impurities, each batch undergoes rigorous bioactivity testing to ensure consistent therapeutic performance, making it a trusted raw material for antidiabetic drug formulation.
This innovative SGLT2 inhibitor stands out for its dual benefits in glycemic control and cardiovascular protection, effectively reducing HbA1c levels while lowering the risk of major adverse cardiovascular events in type 2 diabetes patients. Unlike traditional antidiabetic agents, it does not cause hypoglycemia, and it may even help with modest weight loss by reducing calorie absorption. Its favorable safety profile and multi-target efficacy make it a preferred choice for both prescription drug development and clinical research.
Dapagliflozin (CAS 461432-26-8) caters to diverse professional needs, from pharmaceutical manufacturers producing oral antidiabetic medications to research institutions exploring novel diabetes treatment strategies. Its proven clinical efficacy, pharmaceutical-grade purity, and compliance with international regulatory standards make it a top choice for buyers prioritizing quality and reliability. Whether for large-scale production or small-batch experimental use, this SGLT2 inhibitor delivers unmatched value for diabetes-focused pharmaceutical applications.
